4
|
Li X, Qin J, Cao X, Ren Z, Cui T, Bao Y. The different structure-function correlation as measured by OCT and octopus perimetry cluster analysis in intracranial tumor and glaucoma patients. Front Endocrinol (Lausanne) 2022; 13:938952. [PMID: 35966105 PMCID: PMC9363760 DOI: 10.3389/fendo.2022.938952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2022] [Accepted: 05/31/2022] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND To explore the correlation between visual field (VF) defect values and retinal nerve fiber layer (RNFL) thickness for intracranial tumor and glaucoma patients. METHODS Retrospective analysis is performed for the intracranial and glaucoma patients, whose VF defect values were measured with Octopus perimeter cluster analysis, RNFL thickness, ganglion cell layer (GCL) thickness, and optic disk parameters measured with swept-source OCT. The differences between VF and RNFL (including the data of optic disc) are calculated. The correlation between VF defect values and RNFL and GCL thickness are explored. RESULTS In total 43 eyes of 29 patients with intracranial tumor and 31 eyes of 19 patients with glaucoma were enrolled. The thickness of RNFL not only for the whole (360°), but also for the four quadrants was thinner in the glaucoma group than those of the intracranial tumor group (p<0.05), and similar to the thickness of GCL without significance (p>). There is no significant difference in VF for those two groups except glaucoma having lower sLV (p<0.05). A stronger correlation for mean deviations (MD)s of VF ten clusters and RNFL thickness of OCT twelve sectors is found in the glaucoma patients, but few in the intracranial tumor patients. Logistic regression also shows the loss of RNFL or increasing of vertical CDR and cup volume tending to the diagnosis of glaucoma and the irregular VF damage is inclined to the diagnosis of intracranial tumor. CONCLUSIONS Intracranial tumor has a weak correlation between the RNFL thickness and Octopus VF MD, compared with that of glaucoma. OCT and Octopus VF might provide more helpful information for the differential diagnosis of intracranial tumor and glaucoma.
Collapse
Affiliation(s)
- Xiaochun Li
- Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China
- Department of Ophthalmology, Peking University International Hospital, Beijing, China
| | - Jiayin Qin
- Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China
- Department of Ophthalmology, Peking University International Hospital, Beijing, China
| | - Xiaoguang Cao
- Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China
| | - Zeqin Ren
- Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China
| | - Ting Cui
- Department of Ophthalmology, Peking University International Hospital, Beijing, China
| | - Yongzhen Bao
- Department of Ophthalmology, Peking University People’s Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing, China
- *Correspondence: Yongzhen Bao,
| |
Collapse
|
6
|
Lambe J, Risher H, Filippatou AG, Murphy OC, Sotirchos ES, Ehrhardt H, Ogbuokiri E, Pellegrini N, Toliver B, Luciano NJ, Davis S, Fioravante N, Kwakyi O, Prince JL, Calabresi PA, Fitzgerald KC, Saidha S. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. Neurology 2021; 96:e2525-e2533. [PMID: 33827962 DOI: 10.1212/wnl.0000000000011933] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 02/24/2021] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of patients with RRMS on rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)-and natalizumab-treated patients with RRMS and healthy controls (HCs). METHODS In this observational study, patients with RRMS treated with a single disease-modifying therapy and HCs were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression. RESULTS During the overall follow-up period, rates of GCIPL atrophy were -0.28 ± 0.11 µm/y among rituximab-treated patients with RRMS (n = 35). This was similar to GA-treated (n = 49; -0.33 ± 0.05 µm/y; p = 0.69) and natalizumab-treated patients (n = 88; -0.17 ± 0.10 µm/y; p = 0.13) and faster than HCs (n = 78; -0.15 ± 0.03 µm/y; p = 0.006). Rituximab-treated patients exhibited 0.55 ± 0.23 µm/y faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n = 25; p = 0.02), during which period GCIPL atrophy rates were -0.14 ± 0.13 µm/y. CONCLUSIONS Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, which should be confirmed by larger studies. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence on the difference in rate of change of the GCIPL thickness in patients with RRMS comparing rituximab to other disease-modifying therapies.
Collapse
Affiliation(s)
- Jeffrey Lambe
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Hunter Risher
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Angeliki G Filippatou
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Olwen C Murphy
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Elias S Sotirchos
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Henrik Ehrhardt
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Esther Ogbuokiri
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Nicole Pellegrini
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Brandon Toliver
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Nicholas J Luciano
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Simidele Davis
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Nicholas Fioravante
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Ohemaa Kwakyi
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Jerry L Prince
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Peter A Calabresi
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD
| | - Kathryn C Fitzgerald
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
| | - Shiv Saidha
- From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
| |
Collapse
|
7
|
Ricigliano VA, Tonietto M, Palladino R, Poirion E, De Luca A, Branzoli F, Bera G, Maillart E, Stankoff B, Bodini B. Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study. Mult Scler 2021; 27:528-538. [PMID: 33566723 DOI: 10.1177/1352458520921362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Diffusion-weighted 1H magnetic resonance spectroscopy (DW-MRS) allows to quantify creatine-phosphocreatine brain diffusivity (ADC(tCr)), whose reduction in multiple sclerosis (MS) has been proposed as a proxy of energy dysfunction. OBJECTIVE To investigate whether thalamic ADC(tCr) changes are associated with thalamo-cortical tract damage in MS. METHODS Twenty patients with MS and 13 healthy controls (HC) were enrolled in a DW-MRS and DW imaging (DWI) study. From DW-MRS, ADC(tCr) and total N-acetyl-aspartate diffusivity (ADC(tNAA)) were extracted in the thalami. Three thalamo-cortical tracts and one non-thalamic control tract were reconstructed from DWI. Fractional anisotropy (FA), mean (MD), axial (AD), and radial diffusivity (RD), reflecting microstructural integrity, were extracted for each tract. Associations between thalamic ADC(tCr) and tract metrics were assessed using linear regression models adjusting for age, sex, thalamic volume, thalamic ADC(tNAA), and tract-specific lesion load. RESULTS Lower thalamic ADC(tCr) was associated with higher MD and RD of thalamo-cortical projections in MS (MD: p = 0.029; RD: p = 0.017), but not in HC (MD: p = 0.625, interaction term between thalamic ADC(tCr) and group = 0.019; RD: p = 0.320, interaction term = 0.05). Thalamic ADC(tCr) was not associated with microstructural changes of the control tract. CONCLUSION Reduced thalamic ADC(tCr) correlates with thalamo-cortical tract damage in MS, showing that pathologic changes in thalamic energy metabolism are associated with structural degeneration of connected fibers.
Collapse
Affiliation(s)
- Vito Ag Ricigliano
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France
| | - Matteo Tonietto
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France / Paris-Saclay University, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Fréderic Joliot, Orsay, France
| | - Raffaele Palladino
- Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK/Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Emilie Poirion
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France
| | - Alberto De Luca
- Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Francesca Branzoli
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France / Centre de Neuroimagerie de la Recherche, Paris Brain Institute, ICM, Paris, France
| | - Geraldine Bera
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France
| | | | - Bruno Stankoff
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France / Neurology Department, St Antoine Hospital, APHP, Paris, France
| | - Benedetta Bodini
- Sorbonne University, Paris Brain Institute, ICM, Pitié Salpêtrière Hospital, Inserm UMR S 1127, CNRS UMR 7225, Paris, France / Neurology Department, St Antoine Hospital, APHP, Paris, France
| |
Collapse
|
8
|
Ilardi M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, Serrano L, Joseph B, Wu S, Rucker JC, Balcer LJ, Galetta SL. Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases. J Neurol Sci 2020; 419:117159. [PMID: 33035869 DOI: 10.1016/j.jns.2020.117159] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 09/16/2020] [Accepted: 09/24/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Investigations have found associations of homonymous thinning of the macular ganglion cell/ inner-plexiform layer (GCIPL) with demyelinating lesions in the post-chiasmal visual pathway among patients with multiple sclerosis (MS). Retinal thinning may also occur through retrograde trans-synaptic degeneration, a process by which lesions in post-geniculate visual pathway structures lead to thinning of the GCIPL across thalamic synapses. The purpose of our study was to determine the frequency of homonymous hemimacular thinning that occurs in association with post-chiasmal visual pathway demyelinating lesions in patients with MS and other demyelinating diseases. METHODS Adult patients with demyelinating diseases (MS, neuromyelitis optica spectrum disorder [NMOSD], myelin oligodendrocyte glycoprotein antibody disease (anti-MOG)) who were participants in an ongoing observational study of visual pathway structure and function were analyzed for the presence of hemimacular GCIPL thinning on OCT scans. Brain MRI scans were examined for the presence of post-geniculate visual pathway demyelinating lesions. RESULTS Among 135 participants in the visual pathway study, 5 patients (3.7%) had homonymous hemimacular GCIPL thinning. Eleven patients (8.1%) had a whole+half pattern of GCIPL thinning, characterized by hemimacular thinning in one eye and circumferential macular thinning in the contralateral eye. All but one patient with homonymous hemimacular thinning had demyelinating lesions in the post-geniculate visual pathway; however, these lesions were located in both cerebral hemispheres. CONCLUSION Homonymous hemimacular thinning in the GCIPL by OCT is associated with post-chiasmal visual pathway demyelinating lesions but it appears to be a relatively uncommon contributor to GCIPL loss. Patients with this pattern of GCIPL often fail to complain of hemifield visual loss. Future studies with prospective and detailed MR imaging may be able to more closely associate demyelinating lesions in anatomically appropriate regions of the post-chiasmal visual pathways with homonymous hemimacular thinning.
Collapse
Affiliation(s)
- Marissa Ilardi
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Rachel Nolan-Kenney
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.
| | - Girish Fatterpekar
- Department Radiology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Lisena Hasanaj
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Liliana Serrano
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Binu Joseph
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Shirley Wu
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Janet C Rucker
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Laura J Balcer
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA.
| | - Steven L Galetta
- Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY, USA.
| |
Collapse
|